Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHOCARBAMOL vs ATIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: Tetanus-associated muscle spasms,Off-label: Postoperative muscle spasms
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Terminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Metabolized by the liver via dealkylation and hydroxylation. The major metabolic pathway involves O-dealkylation to form a glycinate conjugate, with CYP450 enzymes likely involved.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Protein binding: 46-50% to albumin.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
Volume of distribution: 0.6-0.8 L/kg. Clinical meaning: distributes widely into tissues, moderate Vd indicating extravascular distribution.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
Oral: high bioavailability, ~80-100% (well absorbed with first-pass metabolism to inactive conjugates). Intravenous: 100%.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
Cr Cl <50 m L/min: Administer every 8-12 hours; Cr Cl <30 m L/min: Administer every 12 hours; hemodialysis: Supplementation not well-defined; avoid if possible due to propylene glycol content.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
Not recommended for children under 16 years; safety and efficacy not established.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
Start at lower end of dosing range (e.g., 750 mg orally 4 times daily) due to increased risk of sedation and falls; monitor renal function and adjust accordingly.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
No FDA black box warning.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
May cause dizziness, drowsiness, or blurred vision; caution with activities requiring mental alertness. Use with caution in patients with hepatic impairment, renal impairment, or myasthenia gravis. Avoid concurrent use with other CNS depressants. May cause urine discoloration (brown, black, or blue).
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Hypersensitivity to methocarbamol or any component of the formulation; concomitant use of anticholinesterase drugs in patients with myasthenia gravis (contraindicated); known history of G6PD deficiency (relative, due to risk of hemolytic anemia).
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
No significant food interactions. Grapefruit juice does not affect methocarbamol. However, avoid alcohol entirely due to additive CNS depression.
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (reduced fetal weight, skeletal ossification delays) at doses 1-3 times human dose; no adequate human studies. Second and third trimesters: Potential for neonatal CNS depression and hypotonia if used near term. Avoid use unless benefit outweighs risk.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
Excreted in breast milk in small amounts; M/P ratio not established. No reported adverse effects in infants. Caution is advised due to potential for CNS depression or muscle weakness.
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
No established dose adjustment guidelines. Increased renal clearance during pregnancy may reduce serum levels; however, safety data insufficient. Use lowest effective dose for shortest duration.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
Methocarbamol is a centrally acting muscle relaxant with sedative properties. Avoid or taper to prevent rebound muscle spasm. Monitor for CNS depression, especially when combined with alcohol or other CNS depressants. Use cautiously in elderly due to fall risk. May cause urine discoloration (brown, black, or blue-green) which is benign. Onset of action is within 30 minutes; maximal effect in 1-2 hours. Typical adult dose: 1.5-2 g PO QID for first 2-3 days, then 1 g QID.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision. Do not drive, operate machinery, or perform hazardous tasks until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation and risk of falls.,Notify your healthcare provider if you experience fever, rash, itching, or jaundice (yellowing of skin/eyes).,Urine may turn brown, black, or blue-green; this is harmless and not a cause for alarm.,Do not stop suddenly; gradual dose reduction is recommended to prevent withdrawal symptoms like muscle spasm or anxiety.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
"The coadministration of propofol, a GABA-A receptor agonist general anesthetic, with methocarbamol, a centrally acting muscle relaxant, can produce additive sedative and respiratory depressant effects. This interaction may lead to excessive sedation, prolonged recovery from anesthesia, and an increased risk of hypoxia or apnea. Clinically, patients may exhibit deeper levels of unconsciousness and require prolonged monitoring of respiratory function."
"Methocarbamol, a centrally acting muscle relaxant, potentiates the sedative effects of nabilone, a synthetic cannabinoid used for chemotherapy-induced nausea and vomiting. This additive central nervous system depression can lead to excessive drowsiness, dizziness, impaired motor coordination, and increased risk of falls or cognitive impairment. Clinically, patients may experience exacerbated sedation, confusion, and psychomotor slowing, particularly when initiating therapy or at higher doses."
"Concomitant use of methocarbamol and gabapentin enacarbil results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic neurotransmission and neuronal excitability. This synergistic interaction significantly increases the risk of excessive sedation, dizziness, and impaired psychomotor function, potentially leading to falls, cognitive deficits, or respiratory depression in susceptible patients. Clinical outcomes are dose-dependent and more pronounced in elderly patients or those with pre-existing CNS compromise."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHOCARBAMOL vs ATIVAN, answered by our medical review team.
METHOCARBAMOL is a Skeletal Muscle Relaxant that works by Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.. ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHOCARBAMOL and ATIVAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHOCARBAMOL is: METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.. The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METHOCARBAMOL and ATIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METHOCARBAMOL is classified as Category A/B. FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (reduced fetal weight, skeletal ossification delays) at doses 1-3 times human dose; no adequate h. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.